Navigating the Complexities of Generics and Biosimilars in Portugal

By Staff Writer

December 5, 2023

The Role and Mission of APOGEN

APOGEN, or the Portuguese Association of Generics and Biosimilars Medicines, is a non-profit organisation founded in 2003. Representing pharmaceutical companies in the Portuguese market, APOGEN’s mission is to promote the concepts of generic and biosimilar medicines. They establish dialogues with stakeholders, including the government and policy makers. They advocate for a more competitive pharmaceutical market.

The Importance of a Thriving Generics Industry

The significance of a thriving generics industry cannot be overstated. However, the introduction of unsustainable cost containment measures has led to product and company withdrawals from the market. This has highlighted the need for greater awareness of the risk of industry unsustainability.

Overcoming Roadblocks to Greater Generic Penetration

Despite generics penetration standing at 51 percent in units and 64.7 percent in the competitive market, Portugal still has significant potential for growth. Barriers such as doubts about the quality and efficacy of generics among doctors, and the pricing and reimbursement system, need to be addressed.

The Future of Generics and Biosimilars in Portugal

Biosimilar medicines offer increased access to life-altering biologic therapies. Although Portugal has implemented measures to facilitate the entry of biosimilar medicines, concerns remain about measures that could compromise the maintenance and launch of new biosimilars in the country.

The EU Pharma Package and APOGEN’s Aspirations

The recent proposal for amending the Pharmaceutical Directive and Regulation signifies a positive move towards the reform of EU pharmaceutical policy. APOGEN urges co-legislators to endorse policies that increase the uptake of generic, biosimilar, and value-added medicines. Therefore, they should also promote timely competition. It’s essential that the adjustment of incentives offers legal certainty for applications of generic and biosimilar medicines.

Bringing Essential Medicine Manufacturing Back to Europe

In conclusion, the outsourcing of essential medicine manufacturing to Asia has proven problematic during times of crisis. Portugal, with its highly skilled workforce and competitive labour costs, could play a crucial role in bringing essential medicine manufacturing back to Europe. 

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.